Table 1 BIRC3 and BIRC5 roles in different cancers

BIRC3

Oral squamous cell carcinoma (OSCC)

Pro-oncogenic: poor prognosis, metastasis, radioresistance

[7, 8]

Chronic lymphocytic leukemia (CLL)

Oncosuppressive: disruptions predict poor prognosis, inferior outcome, chemoresistance. Neg. regulator of the non-canonical NF-kB pathw.

[36,37,38,39,40,41,42,43,44,45, 49]

Chronic lymphocytic leukemia (CLL)

Pro-oncogenic: higher expression in leukemia cells, downregulated by SMAC-mimetics

[50]

Mantle-cell lymphoma (MCL)

Oncosuppressive: mutations activate the non-canonical NF-kB pathw.

[51,52,53,54]

Glioma, glioblastoma (GBM)

Pro-oncogenic: gene expression inversely correlates to survival and therapy resistance. Higher expression in HGG

[3, 12, 56]

Breast cancer

Pro-oncogenic: antiapoptotic, chemoresistance

[57,58,59,60,61,62]

Breast cancer

Oncosuppressive: high expression correlates to drug sensitivity

[2]

BIRC5

Lung, pancreatic, breast, ovarian, brain, colon cancer

Pro-oncogenic

[63,64,65]

B-cell acute lymphoblastic leukemia, B-cell lymphoma and T-cell leukemia/lymphoma

Pro-oncogenic

[66,67,68]

Hepatocellular carcinoma (HCC)

Pro-oncogenic: high expression correlates to lower survival

[70]

Gastrointestinal stromal tumors (GIST)

Pro-oncogenic: high expression correlates to lower survival

[71]

Prostate cancer

Pro-oncogenic: high expression correlates to p53 mutations and metastases. Cytoplasmic localization associates to an aggressive disease

[72, 74]

Gioma, astrocytoma, glioblastoma, medulloblastoma

Pro-oncogenic: anti-apoptotic function. High expression correlates to lower short-term and long-term survival. Overexpression increases chromosomal aberrations

[64, 75,76,77,78,79]

Colorectal cancer, ALL, melanoma, glioblastoma

Pro-oncogenic: silencing and inhibition leads to chemo- and radiosensitization

[80,81,82,83,84]